Merck's Call To Action: Why Industry Should Embrace Health Reform

Industry has much to fear about some elements of health reform, like drug importation and price negotiation under Medicare Part D. But the risks of inaction are even greater. Pharmaceutical companies need to ensure that they have a place at the table-and come with a detailed plan on how health reform should work.

By Kenneth C. Frazier

Kenneth C. Frazier is Merck’s EVP and president of Global Human Health. He made his remarks during a keynote presentation...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Agency Leadership

More from Pink Sheet